Table 3.

Studies of sofosbuvir plus simeprevir with or without ribavirin in recipients with hepatitis C recurrence after liver transplantation

Ref.	No. of patients	Patient characteristics	Antiviral Scheme, (duration)	On treatment virological response (%)	SVR (%)
Pungpapong et al[28]	55	Fibrosis 3-4: 29%, Decompensated cirrhosis: 4%, Cholestatic recurrence: 15%	SOF + SMV ± RBV(12 wk)	98 (EOT)	91
Brown et al[29]	143	Cirrhosis: 60%, MELD score > 10: 14%Previous DAA failure: 9%	SOF + SMV ± RBV (12-24 wk)	-	90
Satokar et al[30]	59	Fibrosis F3/F4: 51%,Treatment experience: 71%	SOF + SMVSOF + SMV + RBVSOF + RBV	62 50 43 (4 wk)	-
Gordon et al[31]	17	Fibrosis: range: 0-4	SOF + SMV(12 wk)	100 (EOT)	-
Gutierrez et al[32]	32	-	SOF + SMV ± RBV(12 wk)	93 (EOT)	-
Punzalan et al[37]	10	Median Fibrosis: 2.5,Treatment experience: 40%	SOF + SMV ± RBV(12 wk)	100 (EOT)	100
Lutchman et al[33]	41	Treatment experience: 56%	SOF + SMV orSOF + RBV(12-24 wk)	100 (8 wk)	-
Nair et al[34]	22	All patients with fibrosis ≥ 3 or decompensated cirrhosis	SOF + SMV ± RBV(12 wk)	100 (EOT)	-
Ripper et al[35]	25	Treatment experience: 64%	SOF + SMV ± RBV(12 wk)	100 (8 wk)	75
O'Dell et al[38]	16	-	SOF + SMV ± RBV	100 EOT	100
Alsabbagh et al[36]	17	Fibrosis F3-4: 40%, Treatment experience: 41%	SOF + SMV (n = 11)SOF + RBV (n = 6)(24 wk)	100 (4 wk)	-

EOT: End of treatment; CTP: Child-Pugh score; DAA: Direct acting antiviral.